Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Pipeline Review, H2 2018

August 2018 | 74 pages | ID: C1B3BC2E3BAEN
Global Markets Direct

Abstracts

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Pipeline Review, H2 2018

SUMMARY

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) pipeline Target constitutes close to 18 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes. The latest report CancerTestis Antigen 1 - Pipeline Review, H2 2018, outlays comprehensive information on the Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Cancer/Testis Antigen 1 is a protein encoded by CTAG1A gene is an antigen that is over expressed in many cancers but that is also expressed in normal ovary and testis tissues which makes it a good candidate for a cancer vaccine. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 8 and 5 respectively.

Similarly, the universities portfolio in Phase I stages comprises 3 molecules, respectively. Report covers products from therapy areas Oncology which include indications Non-Small Cell Lung Cancer, Metastatic Melanoma, Soft Tissue Sarcoma, Synovial Sarcoma, Fallopian Tube Cancer, Metastatic Ovarian Cancer, Gastric Cancer, Glioblastoma Multiforme (GBM), Lung Cancer, Melanoma, Metastatic Breast Cancer, Myxoid Liposarcoma, Ovarian Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Anaplastic Astrocytoma, Breast Cancer, Colorectal Cancer, Epithelial Ovarian Cancer, Ewing Sarcoma, Head And Neck Cancer, Hepatocellular Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Transitional (Urothelial) Tract Cancer, Myelodysplastic Syndrome, Neuroblastoma, Osteosarcoma, Peritoneal Cancer, Prostate Cancer, Rhabdomyosarcoma and Round Cell Liposarcoma.

Furthermore, this report also reviews key players involved in Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B)
• The report reviews Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics and enlists all their major and minor projects
• The report assesses Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Global Markets Direct Report Coverage
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Overview
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Therapeutics Assessment
Assessment by Route of Administration
Assessment by Molecule Type
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Companies Involved in Therapeutics Development
Aduro BioTech Inc
Boehringer Ingelheim GmbH
GlaxoSmithKline Plc
Immune Design Corp
Sanofi Pasteur SA
Scancell Holdings Plc
Vault Pharma Inc
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Drug Profiles
ADU-623 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BI-1361849 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target CTAG1B for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CMB-305 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CMB-305 + G-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CUE-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CYN-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
G-305 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2241658A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMM-65 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LV-305 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SCIB-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SV-283 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target CTAG1A for Gastric Cancer and Hepatocellular Carcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target NY-ESO-1, PRAME, MAGE-A3 and WT-1 for Acute Myeloid Leukemia and Myelodysplastic Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VCP-2292 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VPI-111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Dormant Products
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Discontinued Products
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Product Development Milestones
Featured News & Press Releases
May 24, 2018: Immune Design Announces Launch of Web Portal for SYNOVATE Phase 3 Study of CMB305 Immunotherapy in Synovial Sarcoma
Mar 12, 2018: Immune Design Reports Data Update for Lead Immunotherapy Program: Improvement in Survival for CMB305 Monotherapy in Sarcoma
Oct 16, 2017: Immune Design Announces Positive FDA Feedback on Phase 3 Clinical Trial Design for CMB305 in Synovial Sarcoma Patients
Sep 08, 2017: New Randomized Data From CMB305 + Checkpoint Inhibitor Study Demonstrate Greater Clinical Benefit and Immune Response
Aug 30, 2017: Immune Design Announces New CMB305 + Checkpoint Inhibitor Topline Data from an Upcoming Presentation at the ESMO 2017 Congress
Jun 26, 2017: Scancell Holdings Announces SCIB-2 Patent Granted in Europe
Jun 05, 2017: Immune Design Updates Positive Data from Lead Cancer Immunotherapy Program CMB305 at ASCO Annual Meeting
Jun 01, 2017: Immune responses from early study of novel sarcoma vaccine
May 17, 2017: New Clinical and Biomarker Data Validate Immune Design's CMB305 Program
Oct 10, 2016: Scancell preparing SCIB2 for clinical study in lung cancer
Jun 08, 2016: Immune Design Announces Updated Results For Its Immuno-oncology Product Candidate LV305 at ASCO
Jun 08, 2016: Immune Design Announces Updated Results For Immuno-oncology Product Candidate CMB305 At ASCO
Apr 21, 2016: Immune Design Announces Presentation on LV-305 at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
Feb 09, 2016: Immune Design Announces Positive Topline Data From Phase 1 Clinical Trial of CMB305
Jan 08, 2016: Immune Design Receives Orphan Drug Designation From the U.S. FDA for Complementary Components of CMB305
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Aduro BioTech Inc, H2 2018
Pipeline by Boehringer Ingelheim GmbH, H2 2018
Pipeline by GlaxoSmithKline Plc, H2 2018
Pipeline by Immune Design Corp, H2 2018
Pipeline by Sanofi Pasteur SA, H2 2018
Pipeline by Scancell Holdings Plc, H2 2018
Pipeline by Vault Pharma Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Dormant Products, H2 2018 (Contd.2), H2 2018
Discontinued Products, H2 2018
Discontinued Products, H2 2018 (Contd.1), H2 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

COMPANIES MENTIONED

Aduro BioTech Inc
Boehringer Ingelheim GmbH
GlaxoSmithKline Plc
Immune Design Corp
Sanofi Pasteur SA
Scancell Holdings Plc
Vault Pharma Inc